It is exemplified by the Guardant360® CDx, an FDA-approved liquid biopsy test used as a companion diagnostic for Kirsten Rat Sarcoma Viral Oncogene (KRAS p.G12C) mutation detection in non-small cell lung cancer (NSCLC). Here, KRAS is linked to non-small cell lung carcinoma.